Immune Therapies in Non-Muscle Invasive Bladder Cancer
Philip Levy Ho(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Stephen B. Williams(Cedars-Sinai Medical Center)
Cited by 9
Related Papers
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k
Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo
|Circulation|1998|804
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Epidemiology, Screening, and Prevention of Bladder Cancer
|European Urology Oncology|2022|361